This move is archived. Current quotes and coverage live on the stock page.
Follow REGN
Regeneron Pharmaceuticals faced notable selling pressure, leading to a significant drop in its stock price.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) experienced a decline of 1.45% in its stock price today, closing at CA$795.91. This downturn follows recent shifts in investor sentiment and concerns about the company's growth prospects.
Investor takeaway: Investors should closely monitor Regeneron's commercialization efforts and overall market sentiment, especially in the healthcare sector, as the stock has shown signs of weakness.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$76.86B
P/E
18.5x
Div. yield
0.49%
Div. / share
$3.64
52W high
$859.34
52W low
$551.04
1W change
+1.54%
Beta
0.15
Analyst Price Targets
Based on 27 analysts covering REGN · as of Oct 12, 2026
Wall Street analysts forecast REGN stock price to rise 15.1% over the next 12 months.
Consensus
Buy4.15 / 5.00
Avg. Target
C$859.04
+15.1% Upside
Previously C$856.23 on Oct 9, 2026
Current Price
C$746.54
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.3%
Annualized
90-Day Vol
29.2%
Annualized
Trend (90d)
+40.4%
Annualized drift
90d Mean
C$862.28
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$783.28 | C$710.45 – C$863.58 |
| 60 trading days | C$821.83 | C$715.88 – C$943.46 |
| 90 trading days | C$862.28 | C$728.17 – C$1021.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Regeneron stock drops 1.45%
The stock's decline today reflects broader market concerns about the healthcare sector's performance amidst shifting investor preferences.
Bull case
Regeneron has a solid pipeline of drugs, including Dupixent, which has shown impressive sales growth. This success provides a strong foundation for future revenue.
Bear case
However, the company's slow commercialization efforts for key treatments, especially amid rising competition and market volatility, raise concerns about its growth potential.
Market Reaction
Advertisement
The decline in Regeneron's stock price today is part of a broader pullback in the healthcare sector. Recent investor letters have noted that healthcare stocks are underperforming compared to their industrial counterparts, raising alarms among investors and leading to a cautious approach towards Regeneron.
Investor Sentiment
Concerns about Regeneron's commercialization efforts, particularly for its macular degeneration treatment, have been highlighted in recent reports. American Century Investments expressed disappointment over the stock's limited appreciation potential, prompting a reevaluation of its position in the company. This sentiment likely contributes to the stock's current weakness.
Looking Ahead
As Regeneron navigates these challenges, investors will be watching closely for updates on its drug pipeline and commercialization strategies. The company's ability to adapt to market pressures and enhance its growth prospects will be crucial in determining its stock performance in the coming months.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
